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Abstract 
Patients with Familial adenomatous polyposis coli (FAP) may rarely develop hepatocellular 
adenoma. Here we report the case of a 37 years old FAP woman presenting a hepatocellular 
adenoma after oestroprogestative oral contraception use. In this steatotic adenoma, we 
identified an inactivating biallelic mutation of HNF1. In addition to the known germline 
APC mutation Q1062fs, we did not find an inactivation of the second APC allele nor an 
activation of the ß-catenin target genes GLUL and GPR49. Our findings contrast with two 
hepatocellular adenoma cases related to FAP, for which a biallelic inactivation of the APC 
gene was previously described. Altogether, these results suggest that benign hepatocellular 
carcinogenesis may be dependent or independent of the Wnt/ß-catenin pathway in patients 
with FAP. 
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Introduction 
Hepatocellular adenomas (HCA) are benign liver tumors, most frequently occurring in 
women using oral contraception (1). The other risk factors for HCA are glycogen storage 
diseases and androgen therapy. However, HCA are rare tumors, their estimated incidence in 
France being approximately one case per 100,000 women. 
These tumors result from a benign proliferation of hepatocytes that destroy the normal 
architecture of the liver. They are usually hyper-vascularised and typical adenomas 
correspond to a proliferation of benign hepatocytes, intermingled with numerous thin-walled 
vessels, without portal tracts (2).  
Molecular analysis of HCA revealed that half of the adenoma cases are mutated for the TCF1 
gene, encoding HNF1 (3). These mutations are inactivating and both alleles are mutated in 
tumors. Patients with an inherited mutation in one allele of HNF1 may develop maturity 
onset diabetes of the young type 3 (MODY3, OMIM#600496) and familial liver 
adenomatosis, when the second allele is inactivated in hepatocytes by somatic mutation or 
chromosome deletion (3-5). Mutations of CTNNB1, activating the ß-catenin was also found 
in 15% of the HCA cases (6). Recently, we established a molecular and pathological 
classification of hepatocellular adenomas and showed strong genotype-phenotype correlations 
in 96 analysed cases (7). We also showed that adenomas with ß-catenin activation had a 
higher risk of malignant transformation. 
HCA is also a rare extracolonic tumor developed in patients presenting familial adenomatous 
polyposis coli (FAP). This syndrome is characterized by an early onset of multiple colonic 
adenomatous polyps that progress to colon carcinomas (OMIM: #175100 (8, 9)). In addition 
to colorectal tumors, FAP patients may develop extracolonic tumors, mainly desmoid tumors, 
adenomas and carcinomas of the upper gastrointestinal tract. In colorectal tumors associated 
to FAP, a biallelic inactivation of the APC gene is consistently found and inactivation of the 
APC gene in tumors leads to the ß-catenin accumulation and therefore to the activation of the 
Wnt/wingless pathway. A biallelic inactivation of the APC gene was also recently described 
in extracolonic associated tumors and particularly in two cases of hepatocellular adenoma 
developed in FAP patients (10, 11). 
We tested an HCA found in a FAP woman for particular genetic alterations. We looked for 
mutations in TCF1/HNF1, CTNNB1, encoding ß-catenin, and TP53 genes. Activation of the 
ß-catenin pathway was qualified both by immunohistochemistry to detect ß-catenin and 
Glutamine Synthetase, and by quantification of ß-catenin target genes GLUL, encoding the 
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Glutamine Synthetase and GPR49, encoding an orphan nuclear receptor, using quantitative 
RT-PCR. 
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Material and Methods 
Patient and samples 
A 22 years old woman was treated for FAP in 1983 by a total colectomy and ileo-rectal 
anastomosis for FAP. Pathology showed multiple adenomatous polyps with low grade 
dysplasia. An APC germline mutation, 3184-3187del leading to Q1062fs was identified. 
She was placed under oestroprogestative oral contraception use during 5 years from 1986 to 
1991. Compliance to endoscopic follow-up of the rectum was poor and she was convinced to 
be reoperated in 2001 in order to perform proctectomy and ileo-anal anastomosis. Pre-
operative abdominal ultrasound performed to explore intermittent slight right upper 
abdominal pain revealed a slightly hyper-echoïc homogeneous 7 cm mass on the right liver. 
Magnetic Resonance Imaging showed a T1 hypointense homogeneous mass of liver segment 
VI, slighty hyper intense in T2 sequence and moderately enhanced at arterial phase by intra-
venously injected contrast. The definite diagnosis of hepatic adenoma was confirmed by intra-
operative biopsies of the tumor and of non-tumor tissues performed during proctectomy. 
Pathology of the resected rectum showed multiple adenomatous polyps with low grade 
dysplasia. Two weeks after proctectomy, sudden right hypocondrium pain and hypotension 
occurred, attributed by CT-scan to an intra tumorous hemorrhage of the adenoma. 
Conservative treatment was chosen and successful. A right hepatectomy was performed a few 
months later to remove this symptomatic adenoma, which size of 7 cm remained stable after 
resorption of the intra-tumorous hematoma. Tumor and non-tumor liver samples were frozen 
immediately after surgery and stored at -80°C. The liver specimen was then fixed in 10% 
buffered formalin. Liver samples were paraffin embedded. Post-operative course was 
uneventful. The patient was re-operated in 2005 to resect two recent desmoid tumors of 10 
and 6 cm developed in the anterior abdominal wall. 
 
Mutation screening 
Exons 1 to 10 of TCF1, 2 to 4 of CTNNB1 and codons 1001 to 1111 of APC were screened 
for mutations in the hepatocellular adenoma, using direct sequencing of the exons after 
amplification of the genomic DNA. Protocols were previously described in Bluteau et al. and 
Laurent Puig et al. (3, 12) and are available upon request. 
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Quantitative RT-PCR 
RNA was extracted using RNeasy kit (Qiagen, Valencia, CA) and quantitative RT-PCR was 
performed to quantify the mRNA expression level of GLUL and GPR49, two target genes of 
ß-catenin in the liver (13, 14) as previously described (7). The results were normalized using 
the expression level of the ribosomal RNA R18S and expressed as the n-fold ratio of the gene 
expression in the tested sample compared with the mean of 11 non tumor liver tissues. We 
used as positive controls 10 samples identified as activated for ß-catenin from our previous 
study (7). 
 
Immunohistochemistry 
Paraffin sections were stained with hematein-eosin. Immunostainings were performed with an 
anti-ß-catenin antibody (SantaCruz) and an anti-Glutamine synthetase antibody (BD 
Transduction Laboratories). 
.
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Results and discussion 
On gross examination the lesion measured 7 cm and was well demarcated from the 
surrounding liver, but not encapsulated. It was soft, yellow with no hemorraghe or necrosis 
(Figure 1A). Light microscopy observation revealed that it was composed of benign appearing 
hepatocytes arranged in two-cell thick plates separated by sinusoids and intermingled with 
numerous thin-walled vessels. Hepatocytes showed a marked steatosis (Figure 1B). There was 
no portal triad, ductules, fibrosis, hemorrhage, peliosis or necrosis within the lesion. The 
surrounding non-tumor liver was normal. 
A somatic mutation of HNF1 (787 C>T) leading to an amino acid substitution (R263S) was 
found in the adenoma sample. The mutation appeared homozygous at the RNA level. 
Moreover, genotyping of 3 polymorphisms in the HNF1 gene comparing the non-tumor and 
tumor samples indicated a loss of heterozygosity (LOH) in the tumor. Altogether, these results 
showed a somatic mutation of one HNF1 allele and a somatic deletion of the second HNF1 
allele leading to a biallelic inactivation of the protein. 
Sequencing of the APC gene revealed a heterozygous 4 nucleotides deletion at codon 1062, 
leading to a frameshift. Relative intensity of the mutated peak compared to the normal one 
was similar in both the tumor and the non-tumor sample, indicating the absence of a loss of 
heterozygosity at this locus. No additional somatic mutations of the APC gene were found in 
exon 14. No mutations were identified in CTNNB1, gene encoding the ß-catenin. Consistently 
with the absence of a second event of mutation in APC and the absence of ß-catenin mutation, 
no activation of the Wnt/ß-catenin pathway was detected in the tumor. Indeed, ß-catenin 
target genes were expressed at the same level in the adenoma and in the non-tumor liver 
samples of the FAP patient even when compared to control non-mutated normal liver tissues . 
The lack of Wnt/ß-catenin activation was confirmed by immunohistochemistry: ß-catenin 
immunostaining was observed at the hepatocyte plasma membranes, and no overexpression or 
nuclear reactivity in the adenoma was detected (Figure 1C). Moreover, there was no 
Glutamine Synthetase overexpression in the adenoma compared to the non tumor tissue. 
Two hepatocellular adenoma cases, developed in FAP patients, previously described in the 
literature were described as displaying a biallelic APC inactivation (10, 11). The first patient 
was a 2-years-old girl presenting a non-sense APC germline mutation at codon 1451 and a 
deletion of the second allele in the tumor. In the same tumor, a TP53 mutation (R175H) was 
found. This last result was unusual since TP53 mutations are observed in 20 to 50% of the 
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cases of hepatocellular carcinoma (15), whereas no TP53 mutation were found in a series of 
13 adenomas in Taiwan (6) nor in a series of 30 adenomas in our lab (unpublished data). The 
second case described was a hepatocellular adenoma developed in a 27-years-old woman 
presenting a germline APC mutation at codon 1156 associated with a somatic APC mutation 
at codon 1464, leading to a cytoplasmic accumulation of ß-catenin in the hepatocellular 
adenoma (11). In this last case the information about an oral contraceptive use was not 
available. 
In this present work, morphological characteristics of the hepatocellular adenoma (i.e. 
steatosis in more than 30% of the hepatocytes with no cytological abnormalities, no 
inflammatory infiltrate and lobulated frontiers of the tumors) were characteristic of the 
HNF1 mutated cases described in our recent hepatocellular adenoma classification (7). It is 
very different from the ß-catenin mutated adenomas that usually exhibit cytological 
abnormalities and pseudoglandular formations, without steatosis. 
In conclusion, the present case shows that apart from the Wnt/ß-catenin activation through the 
complete inactivation of APC, benign hepatocarcinogenesis can also occur by an inactivation 
of the tumor suppressor gene encoding HNF1 in a patient with FAP.  
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Figure 1. A: Macroscopy: the liver lesion measured 7 cm, was soft, yellow, well demarcated 
with no hemorraghe or necrosis, B: Microscopy: the lesion was composed of benign 
appearing hepatocytes with marked steatosis, intermingled with thin walled vessels 
(arrow) (HES staining, original magnification x100) C: ß-catenin immunostaining: 
hepatocytes plasma membrane staining with no nuclear reactivity in the hepatocellular 
adenoma (original magnification x200) 
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